About us
Our History
Company overview
Tianming Pharmaceutical, founded in 2010, is a leading innovator in R&D, production, and sales of new drugs, including antibiotics, cardiovascular, diabetes, anti-tumor, anti-aging, and antiviral products. Leveraging our scientific expertise and industry experience, we deliver top-quality pharmaceuticals for research and production.
Renowned for high-quality products, flexibility, and customer service, Tianming has global reach with production bases in China and sales companies in India and Bangladesh, partnering with manufacturers worldwide.
What We Offer
Our factory
Tianming R&D Center’s cutting-edge technology leads the development of new and improved drugs. In the filling workshop, precise operation and meticulous packaging ensure that every product reaches customers with the highest quality. Environmental protection is our compass. We practice green production, implement environmental measures, build a comprehensive safety system, and strive to minimize our carbon footprint.
Our powerful transportation network delivers products worldwide, ensuring seamless connection from raw materials to users, providing high-quality and reliable pharmaceutical solutions for global customers.
Our Vision and Values
Innovative drugs
Tianming Pharmaceuticals is committed to becoming a world-leading biopharmaceutical innovator, constantly breaking through scientific boundaries, and contributing to the cause of human health with outstanding R&D strength and innovative spirit.
With the vision of “making innovative drugs and realizing the dream of health”, while constantly pursuing innovative development, Tianming has successfully won more than 200 patents. It is not only a strong proof of our R&D strength, but also an important milestone for Tianming’s continued deep cultivation and breakthroughs in the field of biopharmaceuticals.
What's News
Latest News at Tianming
ICH Q11 Starting Material Selection: A Practical Guide for Pharmaceutical Intermediate Buyers
Learn how ICH Q11 starting material rules affect pharmaceutical intermediate sourcing—supplier boundaries, COA red flags, and a practical buyer’s checklist.
Polymorphism in Pharmaceutical Intermediates: Why Solid Form Control Matters
This guide explains what polymorphism means for intermediate buyers, how ICH Q6A Decision Tree #4 governs solid form control, which COA red flags signal polymorph gaps, and three questions every buyer should ask their supplier before committing to a purchase.
Elemental Impurities (ICH Q3D) in Pharmaceutical Intermediates: A Buyer’s Guide
This guide explains the four element classes, the 30% control threshold that determines whether routine testing is required, the difference between ICP-MS and ICP-OES analytical methods, and five red flags on supplier COAs that signal inadequate elemental impurity control.